Artificial hypocoagulation in patients with heparin-induced thrombocytopenias (literature review). Part II

Charnaia M.A.; Dement'eva I.I.; Morozov Iu.A.; Gladysheva V.G.; Isaeva A.M.

doi:https://doi.org/

Charnaia M.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Dement'eva I.I.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Morozov Iu.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Gladysheva V.G.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Isaeva A.M.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Artificial hypocoagulation in patients with heparin-induced thrombocytopenias (literature review). Part II

Authors:

Charnaia M.A., Dement'eva I.I., Morozov Iu.A., Gladysheva V.G., Isaeva A.M.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(3): 90‑93

Read: 1154 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Charnaia MA, Dement'eva II, Morozov IuA, Gladysheva VG, Isaeva AM. Artificial hypocoagulation in patients with heparin-induced thrombocytopenias (literature review). Part II. Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(3):90‑93. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Morozov Yu.A., Dement'eva I.I., Charnaya M.A., Gladysheva V.G. Testy na agregatsiyu trombotsitov pri vyyavlenii grupp riska razvitiya geparinindutsirovannoi trombotsitopenii. Kardiologiya i serdechno-sosud khir 2010; 2: 63-67.
Aggarwal A., Sobel B.E., Schneider D.J. Decreased platelet reactivity in blood anticoagulanted with bivalirudin or enoxaparin compared with infractionated heparin: Implications for coronary intervetntion. J Thromb Thrombolysis 2002; 13: 161-165.
Agrawall D.R., Sayeed M.R., Roy I.R., Somaraja K. Pre-emptive use of bivalirudin for emergent off-pump coronary artery bypass surgery in a suspected case of heparin-induced thrombocytopenia. Indian J Anaesth 2012; 56: 1: 98-99.
Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008; 14: 1152-1175.
Antoniou T., Kapetanakis E.I., Thodoraki K. et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum 2002; 5: 4: 354-357.
Aouifi A., Blanc P., Piriou V. et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg 2001; 71: 678-683.
Babuin L., Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010; 6: 813-819.
Chong B.H., Magnani H.N. Danaparoid for the treatment of heparin -induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia, 2nd ed. Eds. T.E. Warkentin, A. Greinacher A. New York: Marcel Dekker Inc 2001; 323-347.
Durand M., Lecompte T., Hacquard M., Carteaux J.P. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. Eur J Cardiothorac Surg 2008; 34: 687-689.
Dyke C.M., Aldea G., Koster A. et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84: 3: 836-839.
Dyke C.M., Koster A., Veale J.J. et al. Pre-emptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg 2005; 80: 299-303.
Edwards J.T., Hamby J.K., Wirrall N.K. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003; 75: 5: 1622-1624.
Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In:. Heparin-Induced Thrombocytopenia, 2nd ed. Eds. T.E. Warkentin, A. Greinacher. New York: Marcel Dekker Inc 2001; 349-380.
Hajj-Chahine J., Jayle C., Tomasi J., Corbi P. Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. Interact. CardioVasc Thorac Surg 2010; 11: 5: 679-681.
Jovic M.D., Nezic D.G., Calija B.M. et al. Cardiac surgery in patients with heparin-induced thrombocytopenia (HIT II). Acta Chir Iugosl 2009; 56: 1: 47-52.
Koster A., Meyer O., Fischer T. et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001; 122: 6: 1254-1255.
Lewis B.E., Matthai W.H., Cohen M. et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57: 177-184.
Linkins L.A., Dans A.L., Moores L.K. et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 2: Suppl: 495S-530S.
Lubenow N., Selleng S., Wollert H.G. et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003; 75: 2: 577-579.
Mangani H.N., Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 6: 967-981.
Merry A.F., Paudkivi P.J., Middleton N.G. et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77: 3: 925-931.
Neuray M., Balling G., Schreiber C., Martin K. Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban. Ann Thorac Surg 2012; 94: 2: 653-655.
Nutescu E.A., Shapiro N.L., Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin 2008; 26: 169-187.
Ohteki H., Furukawa K., Ohnishi H. et al. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000; 48: 39-46.
Palatianos G.M., Foroulis C.N., Vassili M.I. et al. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost. J Thorac Cardiovasc Surg 2004; 127: 2: 548-554.
Pineau E., Le Bret E., Folliguet T. et al. Use of Organon, a synthetic heparinoid, in two cardiopulmonary bypass procedures in the same patient sensitive to heparin. Arch Mal Couer Vaiss 2001; 94: 2: 144-147.
PÖtzsch B., KlÖvekorn W.P., Madlener K. Use of Heparin during Cardiopulmonary Bypass in Patients with a History of Heparin-Induced Thrombocytopenia. N Engl J Med 2000; 343: 515.
Reiss F.C. Anticoagulation management and cardiac surgery in patients with heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg 2005; 17: 1: 85-96.
Selleng S., Haneya A., Hirt S. et al. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 2008; 112: 10: 4024-4027.
von Segesser L.K., Mueller X., Marty B. et al. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass. Perfusion 2002; 17: 2: 411-416.
Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131.